Why the study?
Does treatment with high doses of ACE-inhibitors, spironolactone, and beta-blockers improve clinical symptoms, diastolic function, and survival in patients with systolic heart failure (EF < 40%)?
Does treatment with high doses of ACE-inhibitors, spironolactone, and beta-blockers improve clinical symptoms, diastolic function, and survival in patients with systolic heart failure (EF < 40%)?
Answers are grounded in this paper and cite their sources.
High-dose GDMT may aid systolic HF symptoms; Level 5 data leaves causal survival effects open.
Department of Cardiology, General Hospital "Prim. dr Abdulah Nakas", Kranjcevićeva 12, 71000 Sarajevo, Bosnia and Herzegovina.Twenty seven patients diagnosed as having systolic heart failure with Ejection Fraction (EF) of less than 40% by echocardiography were monitored over a period of 3 years. The monitored parameters included clinical symptoms, diastolic dysfunction, therapies and survival during three years of treatment. The results indicate a beneficial effect of treatment with high doses of ACE-inhibitors, spironolactone and beta-blockers in improving clinical symptoms and diastolic function. The survival rate was similar to that in the developed European countries.
No takes yet. Share an insight, caveat, or question.
Macić-Džanković et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: